HTB

FDA warning of drug interactions between boceprevir and some HIV protease inhibitors

The US FDA have notified health care professional and patients that drug interactions between boceprevir and certain ritonavir- boosted HIV protease inhibitors (atazanavir, lopinavir and darunavir) can significantly reduce the effectiveness of these drugs when used together. [1]

Merck, the manufacturer’s of boceprevir also issued a drug warning giving the pharmacokinetic data and the recommendation that “coadministering boceprevir and ritonavir-boosted PIs is not recommended”. [2]

Source: FDA list serve

References:

  1. FDA warning. Victrelis (boceprevir) and ritonavir-boosted Human Immunodeficiency Virus (HIV) protease inhibitor drugs: drug safety communication – drug interactions, (9 February 2012).
    http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm291144.htm
  2. Merck. Dear Healthcare Professional letter. Results of pharmacokinetic study in healthy volunteers given VICTRELIS (boceprevir) and ritonavir-boosted HIV protease inhibitors may indicate clinically significant drug interactions for patients coinfected with chronic hepatitis C and HIV. (6 February 2012).
    http://www.merck.com/newsroom/pdf/FINAL_DHCP_2_6_2012.pdf

Links to other websites are current at date of posting but not maintained.